Federal contract award
75A50122C00078
IT IS ESTIMATED THAT JUST 5,000 US PHARMACIES OFFER POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS WITH THE OTHER 83,000 LOCATIONS ONLY OFFERING SAMPLE COLLECTION / SEND OUT SERVICES OR PROVIDING NO TESTING AT ALL. IN THIS EFFORT, LUMINEX CORPORATION, A
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $31.0M |
| Current contract value | $31.0M |
| Potential contract value / ceiling | $31.0M |
| Start date | Sep 30, 2022 |
| Current end date | Jun 30, 2026 |
| Potential end date | Jun 30, 2026 |
| Latest award activity | Apr 15, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 15, 2025 | P00005 | $0 | POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS PLATFORM FOR A DISTRIBUTED PHARMACY NETWORK IN THIS EFFORT, LUMINEX CORPORATION, A DIASORIN COMPANY, AIMS TO UNLOCK THIS UNREALIZED POTENTIAL FOR DISEASE DETECTION AND CONTROL BY DEVELOPING, VERIFYING AND C |
| Oct 9, 2024 | P00004 | $0 | POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS PLATFORM FOR A DISTRIBUTED PHARMACY NETWORK IN THIS EFFORT, LUMINEX CORPORATION, A DIASORIN COMPANY, AIMS TO UNLOCK THIS UNREALIZED POTENTIAL FOR DISEASE DETECTION AND CONTROL BY DEVELOPING, VERIFYING AND C |
| Jul 9, 2024 | P00003 | $0 | POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS PLATFORM FOR A DISTRIBUTED PHARMACY NETWORK IN THIS EFFORT, LUMINEX CORPORATION, A DIASORIN COMPANY, AIMS TO UNLOCK THIS UNREALIZED POTENTIAL FOR DISEASE DETECTION AND CONTROL BY DEVELOPING, VERIFYING AND C |
| Jul 31, 2023 | P00002 | $0 | POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS PLATFORM FOR A DISTRIBUTED PHARMACY NETWORK IN THIS EFFORT, LUMINEX CORPORATION, A DIASORIN COMPANY, AIMS TO UNLOCK THIS UNREALIZED POTENTIAL FOR DISEASE DETECTION AND CONTROL BY DEVELOPING, VERIFYING AND C |
| Jan 5, 2023 | P00001 | $0 | IT IS ESTIMATED THAT JUST 5,000 US PHARMACIES OFFER POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS WITH THE OTHER 83,000 LOCATIONS ONLY OFFERING SAMPLE COLLECTION / SEND OUT SERVICES OR PROVIDING NO TESTING AT ALL. IN THIS EFFORT, LUMINEX CORPORATION, A |
| Sep 28, 2022 | 0 | $31.0M | IT IS ESTIMATED THAT JUST 5,000 US PHARMACIES OFFER POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS WITH THE OTHER 83,000 LOCATIONS ONLY OFFERING SAMPLE COLLECTION / SEND OUT SERVICES OR PROVIDING NO TESTING AT ALL. IN THIS EFFORT, LUMINEX CORPORATION, A |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.